Results 201 to 210 of about 2,649 (263)

Proteasome inhibitor, ixazomib prevents topoisomerase‐I degradation and reverses irinotecan resistance in colorectal cancer

Molecular Oncology, EarlyView.
Ixazomib inhibits proteasome‐mediated degradation of topoisomerase I induced by irinotecan, thereby restoring drug sensitivity and promoting tumor cell death in colorectal cancer. Irinotecan, a topoisomerase I (topoI) inhibitor, is widely used for colorectal cancer, but resistance remains a major clinical challenge.
Yuho Ebata, Koji Ando, Hirofumi Hasuda, Koshi Mimori, Elizabeth C. Unan, Siddhartha Pulukuri, Aahana Tiku, Allison Berger, Eiji Oki, Ajit Bharti, Tomoharu Yoshizumi   +10 more
wiley   +1 more source

From Self-Management to Shared-Management: A Relational Approach for Equitable Chronic Care. [PDF]

Public Health Ethics
Stutzin Donoso F.
europepmc   +1 more source

Augmented authenticity in athlete branding through human-AI co-production. [PDF]

Front Sports Act Living
Westerbeek H.
europepmc   +1 more source

Well-Being Economies: A Harder but Still Important Health Advocacy Goal; A Response to Recent Commentaries. [PDF]

Int J Health Policy Manag
Labonté R.
europepmc   +1 more source

Much Ado About Gender. [PDF]

Arch Sex Behav
Solander T.
europepmc   +1 more source

Are we truly fighting ableism? Digressions for a complex society. [PDF]

Front Sociol
da Silva LT, Abramov DM, Quintanilha DF.
europepmc   +1 more source

Psychosocial factors at work and their impact on health: contributions to current debates. [PDF]

Rev Bras Med Trab
Fischer FM, Martinez MC.
europepmc   +1 more source